Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
Citations Over TimeTop 10% of 1997 papers
Abstract
A combination AIDS vaccine approach consisting of priming with adenovirus-HIV-1MN gp160 recombinants followed by boosting with HIV-1SF2 gp120 was evaluated in chimpanzees. Long-lasting protection, requiring only three immunizations, was achieved against a low-dose challenge with the SF2 strain of HIV-1 and a subsequent high-dose SF2 challenge administered 1 year later without an intervening boost. Notably, neutralizing antibody responses against both clinical and laboratory isolates developed in three chimpanzees and persisted until the time of high-dose challenge. The possibility that cytotoxic T-lymphocytes contribute to low-dose protection of a chimpanzee lacking neutralizing antibodies is suggested. Our results validate the live vector priming/subunit booster approach and should stimulate interest in assessing this combination vaccine approach in humans.
Related Papers
- → Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine(2022)15 cited
- → Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2(2022)13 cited
- → Effectiveness and duration of a second COVID-19 vaccine booster(2022)2 cited
- STUDY ON IMMUNORESPONSIBILITY TO BOOSTER INJECTION OF HBV VACCINATION(1993)
- → Protection following BNT162b2 booster substantially exceeds that of a fresh 2-dose vaccine: a quasi-experimental study(2021)